- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04777916
Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML) (ALFAPPP)
A Prospective Non-interventional Study Documenting the Management and Outcomes of Adult Patients With Acute Myeloid Leukemia (AML)
Study Overview
Status
Conditions
Detailed Description
During the last fifteen years, the landscape of AML diagnosis and therapeutical options has markedly evolved. Refined genetic and prognostic characterizations, together with new drug approvals and new allogeneic hematopoietic stem cell transplantation (HSCT) procedures, have increased patient journey diversity.
I - At initial AML diagnosis, not all newly diagnosed patients are entering clinical trials. A substantial proportion of them are treated with standard therapies outside of any trial. To date, the standard approved frontline treatment options include:
- Standard intensive 3+7 (anthracycline + cytarabine) chemotherapy ± an approved FLT3 inhibitor (midostaurine, Rydapt®), according to different dose schedules in older versus younger patients
- Combination of sequential gemtuzumab ozogamicin (GO, Mylotarg®) with 3+7
- Liposomal formulation of daunorubicin + cytarabine (CPX-351, Vyxeos®)
- Less intensive chemotherapy with azacytidine or low dose cytarabine (LDAC) in patients considered as not eligible for the more intensive options above
The investigator's choice is guided by AML and patient's characteristics, and by the approved indications for each of these treatment options. This study will thus start including these specific options. Further study amendments might be necessary in case of new standard treatment definition.
II - Secondly, no specific salvage regimen has emerged as a standard in patients with primary refractory or relapsed AML (R/R AML). R/R AML is thus an important field for investigational new drugs (INDs) and precision medicine development. To date, the only IND approved to treat R/R AML is gilteritinib for FLT3-mutated AML patients. The French agency ANSM also allow to use GO for treating R/R AML patients in the frame of a RTU (Recommendation Temporaire d'Utilisation).
In the "real life", because of the multiplicity of treatments used in these patients, some of them being now quite efficient, it has become difficult to accurately describe the general outcome of R/R AML patients.
III - Thirdly, allogeneic HSCT is no more considered at the ultimate and final goal of AML therapy in all patients, as it was in the past. Transplant indications have been better described and HSCT in now evaluated in the context of the whole treatment course, including pre- and post-transplant therapy, as well as pre- and post-transplant minimal residual disease (MRD) levels.
For all these reasons, it is of utmost importance to document the various characteristics, treatments and outcomes of patients treated in the real-life, outside of clinical trials, for 1) real-world treatment evaluation; 2) post-approval use of recently approved drugs; 3) standardization and improvement of routine patient management; and 4) better disease understanding.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Karine CELLI LEBRAS, Mrs
- Phone Number: 33 1 57 27 67 17
- Email: karine.celli-lebras@aphp.fr
Study Contact Backup
- Name: Hervé DOMBRET, MD-Prof
- Phone Number: 33 1 57 27 67 17
- Email: herve.dombret@mac.com
Study Locations
-
-
-
Amiens, France
- Recruiting
- CHU Amiens
-
Contact:
- Delphine LEBON, MD
-
Argenteuil, France
- Recruiting
- Centre Hospitalier Victor Dupouy
-
Contact:
- Ahmad AL JIJAKLI, MD
-
Bobigny, France
- Recruiting
- AP-HP-GHU - Hôpital AVICENNE
-
Contact:
- Thorsten BRAUN, MD-Prof
-
Caen, France
- Recruiting
- CHU de la cote de Nacre
-
Contact:
- Sylvain CHANTEPIE, MD
-
Clamart, France
- Recruiting
- Hôpital MILITAIRE PERCY
-
Contact:
- Jean-Valère MALFUSON, MD-Prof
-
Corbeil-Essonnes, France
- Recruiting
- Centre Hospitalier Sud Francilien
-
Contact:
- Stéphanie HAIAT, MD
-
Créteil, France
- Recruiting
- Hôpital Henri Mondor AP-HP
-
Contact:
- Cécile PAUTAS, MD
-
Dijon, France, 21000
- Active, not recruiting
- CHU Dijon- François Mitterrand
-
Dunkerque, France
- Recruiting
- Centre Hospitalier de Dunkerque
-
Contact:
- Kevin James WATTEBLED, MD
-
Le Chesnay, France
- Recruiting
- Centre Hospitalier de Versailles André Mignot
-
Contact:
- Juliette LAMBERT, MD
-
Lens, France
- Recruiting
- Centre Hospitalier Dr Schaffner
-
Contact:
- Claire BORIES, MD
-
Lille, France
- Recruiting
- CHRU de Lille- Hopital C. HURIEZ
-
Contact:
- Céline BERTHON, MD
-
Lille, France
- Recruiting
- GHICL-Hopital St Vincent de Paul
-
Contact:
- Benjamin CARPENTIER, MD
-
Limoges, France
- Recruiting
- C H U DE LIMOGES- Hopital Dupuytren
-
Contact:
- Pascal TURLURE, MD
-
Marseille, France
- Recruiting
- CHU la Conception
-
Contact:
- Laure FARNAULT, MD
-
Meaux, France
- Recruiting
- Centre Hopsitalier de l'Est Francilien - Site de Meaux
-
Contact:
- Jamilé FRAYFER, MD
-
Nice, France
- Recruiting
- Centre Antoine Lacassagne
-
Contact:
- Anna BORRA, MD
-
Nice, France
- Recruiting
- CHU Nice,Hopital Archet 1
-
Contact:
- Thomas CLUZEAU, MD-Prof
-
Paris, France
- Recruiting
- Hopital Pitie-Salpetriere APHP
-
Contact:
- Madalina UZUNOV, MD
-
Paris, France
- Recruiting
- Hôpital Necker - APHP
-
Contact:
- Ambroise MARCAIS, MD
-
Paris, France
- Recruiting
- Hôpital Saint Louis- APHP
-
Contact:
- Raphaël ITZYKSON, MD-Prof
-
Paris, France
- Recruiting
- Hôpital SAINT ANTOINE-APHP
-
Contact:
- Ollivier LEGRAND, MD-Prof
-
Pierre-Bénite, France
- Recruiting
- Centre Hospitalier Lyon Sud
-
Contact:
- Maël HEIBLIG, MD
-
Pontoise, France
- Recruiting
- Centre Hospitalier Rene Dubos
-
Contact:
- Iona VAIDA, MD
-
Roubaix, France
- Recruiting
- Centre Hospitalier de Roubaix
-
Contact:
- Isabelle PLANTIER, MD
-
Rouen, France
- Recruiting
- Centre Henri Becquerel
-
Contact:
- Emilie LEMASLE, MD
-
Saint-Cloud, France
- Not yet recruiting
- Institut Curie - Hôpital René Huguenin
-
Contact:
- Jacques VARGAFTIG, MD
-
Saint-Quentin, France
- Recruiting
- Centre Hospitalier de St Quentin
-
Contact:
- Reda GARIDI, MD
-
Valenciennes, France
- Not yet recruiting
- Centre Hospitalier Valenciennes
-
Contact:
- Sabine TRICOT, MD
-
Villejuif, France
- Recruiting
- Institut Gustave Roussy
-
Contact:
- Jean-Baptiste MICOL, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient aged 18 years old or more
- Patient with newly diagnosed previously untreated de novo, secondary or therapy-related AML
- Patients with R/R de novo, secondary or therapy-related AML
- Patient with Health insurance
Exclusion Criteria:
- Acute promyelocytic leukemia
- AML which is not morphologically proven (patients with granulocytic sarcoma may be included)
- For newly diagnosed AML: previous treatment of leukemia apart from hydroxyurea. Previous anti leukemia treatments are allowed if they were administered before the diagnosis of AML to treat a MDS, MPN, MPN/MDS or CML
- Opposition of the patient to participate to this non-interventional study
More specific eligibility criteria might be requested to enter some study modules
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Standard intensive 3+7 YOUNG OR ELDERLY
Standard intensive 3+7 (anthracycline + cytarabine) chemotherapy ± an approved FLT3 inhibitor (midostaurine, Rydapt®), according to different dose schedules in older versus younger patients
|
GO, Mylotarg®) with 3+7
Combination of sequential gemtuzumab ozogamicin (GO, Mylotarg®) with 3+7
|
CPX-351, Vyxeos®)
Liposomal formulation of daunorubicin + cytarabine (CPX-351, Vyxeos®)
|
Lower intensity chemotherapy with azacytidine or low dose cytarabine (LDAC)
Lower intensity chemotherapy with azacytidine or low dose cytarabine (LDAC) in patients considered as not eligible for the more intensive options above
|
Refractory or relapsed AML
Secondly, no specific salvage regimen has emerged as a standard in patients with primary refractory or relapsed AML (R/R AML). R/R AML is thus an important field for investigational new drugs (INDs) and precision medicine development. To date, the only IND approved to treat R/R AML is gilteritinib for FLT3-mutated AML patients. The French agency ANSM also allow to use GO for treating R/R AML patients in the frame of a RTU (Recommendation Temporaire d'Utilisation). In the "real life", because of the multiplicity of treatments used in these patients, some of them being now quite efficient, it has become difficult to accurately describe the general outcome of R/R AML patients. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OS
Time Frame: 1 year
|
The primary objective of this multicenter non-interventional study is to record and prospectively evaluate the real-life characteristics, treatments and outcomes of adult patients with newly diagnosed or R/R AML, when managed and treated in the French ALFA centers according to standard practices outside of a clinical trial. The two co-primary endpoints are event-free (EFS) and overall survival (OS) estimations at 1, 3, 5 and 10 years:
|
1 year
|
OS
Time Frame: 3 years
|
The primary objective of this multicenter non-interventional study is to record and prospectively evaluate the real-life characteristics, treatments and outcomes of adult patients with newly diagnosed or R/R AML, when managed and treated in the French ALFA centers according to standard practices outside of a clinical trial. The two co-primary endpoints are event-free (EFS) and overall survival (OS) estimations at 1, 3, 5 and 10 years:
|
3 years
|
OS
Time Frame: 5 years
|
The primary objective of this multicenter non-interventional study is to record and prospectively evaluate the real-life characteristics, treatments and outcomes of adult patients with newly diagnosed or R/R AML, when managed and treated in the French ALFA centers according to standard practices outside of a clinical trial. The two co-primary endpoints are event-free (EFS) and overall survival (OS) estimations at 1, 3, 5 and 10 years:
|
5 years
|
OS
Time Frame: 10 years
|
The primary objective of this multicenter non-interventional study is to record and prospectively evaluate the real-life characteristics, treatments and outcomes of adult patients with newly diagnosed or R/R AML, when managed and treated in the French ALFA centers according to standard practices outside of a clinical trial. The two co-primary endpoints are event-free (EFS) and overall survival (OS) estimations at 1, 3, 5 and 10 years:
|
10 years
|
EFS
Time Frame: 1 year
|
The primary objective of this multicenter non-interventional study is to record and prospectively evaluate the real-life characteristics, treatments and outcomes of adult patients with newly diagnosed or R/R AML, when managed and treated in the French ALFA centers according to standard practices outside of a clinical trial. The two co-primary endpoints are event-free (EFS) and overall survival (OS) estimations at 1, 3, 5 and 10 years:
|
1 year
|
EFS
Time Frame: 3 years
|
The primary objective of this multicenter non-interventional study is to record and prospectively evaluate the real-life characteristics, treatments and outcomes of adult patients with newly diagnosed or R/R AML, when managed and treated in the French ALFA centers according to standard practices outside of a clinical trial. The two co-primary endpoints are event-free (EFS) and overall survival (OS) estimations at 1, 3, 5 and 10 years:
|
3 years
|
EFS
Time Frame: 5 years
|
The primary objective of this multicenter non-interventional study is to record and prospectively evaluate the real-life characteristics, treatments and outcomes of adult patients with newly diagnosed or R/R AML, when managed and treated in the French ALFA centers according to standard practices outside of a clinical trial. The two co-primary endpoints are event-free (EFS) and overall survival (OS) estimations at 1, 3, 5 and 10 years:
|
5 years
|
EFS
Time Frame: 10 years
|
The primary objective of this multicenter non-interventional study is to record and prospectively evaluate the real-life characteristics, treatments and outcomes of adult patients with newly diagnosed or R/R AML, when managed and treated in the French ALFA centers according to standard practices outside of a clinical trial. The two co-primary endpoints are event-free (EFS) and overall survival (OS) estimations at 1, 3, 5 and 10 years:
|
10 years
|
Collaborators and Investigators
Investigators
- Study Chair: Hervé DOMBRET, PD-Prof, Acute Leukemia French Association
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ALFA PPP Study
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia (AML)
-
Goethe UniversityCompleted
-
Daiichi Sankyo, Inc.CompletedAMLUnited States, Korea, Republic of, Taiwan, United Kingdom, France, Australia, Spain, Italy, Canada, Singapore, Germany, Netherlands, Hong Kong, Belgium, Croatia, Czechia, Hungary, Poland, Serbia
-
Gemin XCompleted
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingNewly Diagnosed Acute Myeloid Leukemia (AML)China
-
Zhejiang ACEA Pharmaceutical Co. Ltd.Recruiting
-
German Cancer Research CenterUniversity Hospital Heidelberg; University Hospital DresdenNot yet recruitingRelapsed/Refractory Acute Myeloid Leukemia (AML)Germany
-
Georgetown UniversityNational Heart, Lung, and Blood Institute (NHLBI); Jazz PharmaceuticalsRecruitingAcute Myeloid Leukemia (AML) in RemissionUnited States
-
Tarapeutics Science Inc.RecruitingRelapsed or Refractory Acute Myeloid Leukemia (AML)China
-
The First Affiliated Hospital of Xiamen UniversityFujian Cancer Hospital; Huizhou Municipal Central Hospital; Chipscreen Biosciences... and other collaboratorsRecruitingLeukemia, Myeloid, Acute | AML Stage, AdultChina
-
The First Affiliated Hospital of Soochow UniversityRecruitingAcute Myeloid Leukemia (AML) in RemissionChina